Biochemistry-first molecular monograph · Version 5.0 · Updated 23 August 2026
MOTS-c
A mitochondrial-derived metabolic signalling peptide
MOTS-c links mitochondrial coding to cellular nutrient sensing and can translocate to the nucleus under metabolic stress.
This monograph distinguishes endogenous MOTS-c physiology from administration of an exogenous MOTS-c preparation. It maps mitochondrial coding, metabolic-stress signalling, nuclear translocation, animal physiology and the absence of an adequate human therapeutic exposure programme.
This monograph begins with the molecule and follows the causal chain through biochemistry, cellular mechanism, exposure and integrated physiology. Population studies enter only at the terminal stress-test: useful for the proposition actually tested, incapable of defining the molecule or replacing the causal model.
Epistemological position
The causal chain carries the science.
Identity establishes what exists. Biochemistry establishes what can react. Pharmacology establishes whether the reaction is reachable. Physiology establishes what the system does with it. Statistical human observation comes last and adjudicates only the route, exposure, population and outcome actually studied.
A population average cannot identify a molecule, create a mechanism or decide an individual response. A demonstrated mechanism remains bounded by the causal step shown; a terminal study can confirm or refute its translation under specified conditions, never rewrite the underlying chemistry.
Molecular dossier
The entity before the outcome.
- ENTITY
- 16-residue mitochondrial-derived peptide encoded within 12S rRNA
- BIOCHEMICAL CLASS
- Mitonuclear metabolic signalling peptide
- PRIMARY SYSTEM
- Folate/purine stress · AICAR · AMPK · nuclear stress-response programmes
- IDENTITY BOUNDARY
- Endogenous MOTS-c concentration, genotype and synthetic exogenous administration are different scientific objects. Association studies cannot supply administered-product PK.
Action ledger
Describe the action before judging its value.
Benefit is a downstream clinical judgement. The scientific object is the action itself: what moves, under which exposure, in which biological state, and where the inference stops.
Attributed biochemical action
MOTS-c links mitochondrial coding to cellular nutrient sensing and can translocate to the nucleus under metabolic stress.
Exposure and reachability
Exogenous administration improves selected metabolic and performance outcomes in animal models. Human pharmacokinetics, immunogenicity and target-engagement after administration remain insufficiently characterised.
Physiological direction is contextual
MOTS-c biology connects mitochondrial stress sensing with cytosolic purine metabolism, AMPK and nuclear adaptation. The sign of that response depends on energy state, tissue, age and proliferative demand: an energy-conservation programme may improve metabolic resilience yet constrain growth or repair in another compartment. Endogenous concentration and injected exposure are separate physiological questions.
Individual adjudication boundary
Human exogenous exposure, immunogenicity and a validated administered-peptide target-engagement signature. An exercise-associated endogenous signal does not prove that injection reproduces exercise adaptation or benefits cellular regeneration.
Causal map with terminal adjudication
The scientific hierarchy is explicit.
I–II strong; III preclinical for administered peptide
MOTS-c links mitochondrial coding to cellular nutrient sensing and can translocate to the nucleus under metabolic stress.
Class D/E for therapeutic administration
This descriptor applies only to the named route, population and outcome. It neither ranks nor creates the molecule’s biochemical science.
Translation boundary
Human exogenous exposure, immunogenicity and a validated administered-peptide target-engagement signature.
What must not be inferred
An exercise-associated endogenous signal does not prove that injection reproduces exercise adaptation or benefits cellular regeneration.
Historical and international corpus
Old research is not absent research.
MOTS-c was identified in 2015. It is genuinely recent, although it belongs to the older fields of mitochondrial genetics, purine metabolism and AMPK signalling.
Its youth should not diminish the chemical coherence of the AICAR–AMPK–nuclear-response chain, and its mechanistic elegance should not invent exogenous human pharmacology.
A new mitochondrial coding proposition
Identification of a 16-residue peptide encoded within mitochondrial 12S rRNA changed the scientific object: mitochondrial sequence could contribute a regulatory peptide rather than only canonical respiratory proteins and RNAs.[1]
Mitonuclear signalling and human association diverge
Nuclear translocation, stress-responsive transcription, exercise-associated circulation and genotype studies expanded the mechanism. None measures the PK of a synthetic injected preparation.[2][3][4][5][6]
Mechanistic and biochemical calculus
Constraint, measurement and inference are not the same claim.
A biochemical proposition can be powerful without a clinical trial, but its premises, exposure and domain must remain explicit. Each statement below is labelled by the operation that supports it.
Endogenous and administered MOTS-c are different variables
Endogenous production, circulating measurement, mitochondrial genotype and exogenous dose have different source terms. They cannot be substituted in a causal model.[1][2][3]
Purine stress provides a coherent biochemical bridge
Perturbation of folate and de-novo-purine metabolism, AICAR accumulation and AMPK activation connect peptide exposure to an energy-stress response through measurable intermediates.[1][4]
Mechanistic sign depends on the tissue objective
A recent stromal-cell system showed metabolic signalling alongside impaired reparative behaviour. This directly falsifies the idea that AMPK engagement or a mitochondrial origin is inherently regenerative.[7]
Complete scientific web editionOpen the full causal analysis and referencesThe decision-grade summary remains above. The complete publication stays available here and as a downloadable PDF.
Causal architecture
From molecular event to organismal hypothesis.
Mitochondrial coding is the first distinction
MOTS-c originates from a short open reading frame within mitochondrial 12S rRNA. This identity situates the peptide within mitonuclear communication, not merely among circulating metabolic hormones.[1]
Metabolic signalling is not synonymous with repair
Recent stromal-cell work couples AMPK movement with reduced proliferation and impaired reparative behaviour in the studied setting. This counterexample demonstrates that a valid mechanism can produce an undesirable outcome for a different biological objective.[7]
What is established
✓ Mitochondrial coding origin
✓ AMPK and metabolic-stress biology
✓ Human endogenous associations
What remains unresolved
? Human exogenous PK
? Immunogenicity
? Controlled therapeutic efficacy
Causal hierarchy
Seven evidentiary layers. No category substitution.
Levels I-V build the causal and translational model. Human observations and controlled clinical trials then test the complete proposition under the route, exposure, population and outcome actually studied. A trial is terminal adjudication, not the source of molecular truth.
IMolecular identity and chemistryWhat exact sequence, terminal chemistry, formulation and route exist?
IIBiochemistry and target architectureWhat reactions, binding events and signalling steps are physically possible?
IIICells and ex-vivo tissuesWhat changes in the relevant cell or isolated tissue system?
IVAnimal and in-vivo pharmacologyDoes exposure reach the mechanism in an integrated organism?
VIntegrated physiology and translationHow do tissue state, feedback, dose and individual terrain alter the response?
VIHuman PK and observational signalIs the entity present, tolerated and associated with a signal in humans?
VIIControlled clinical trialsDoes the specified protocol change a prespecified patient-relevant outcome?
Method applied to MOTS-c
Where this molecule’s evidence can, and cannot, travel.
The complete corpus-wide attribution rules are published in the scientific methodology. This is their molecule-specific application.
Entity rule applied
Endogenous MOTS-c concentration, genotype and synthetic exogenous administration are different scientific objects. Association studies cannot supply administered-product PK.
Reachability rule applied
Exogenous administration improves selected metabolic and performance outcomes in animal models. Human pharmacokinetics, immunogenicity and target-engagement after administration remain insufficiently characterised. The decisive exposure boundary for MOTS-c therefore remains molecule-, formulation- and route-specific.
Causal-strength rule applied
MOTS-c links mitochondrial coding to cellular nutrient sensing and can translocate to the nucleus under metabolic stress. This places the present causal depth at i–ii strong; iii preclinical for administered peptide. That grade describes which links in the mechanism have been demonstrated; it is not a consumer rating and cannot be converted into a general promise of benefit.
Human-adjudication rule applied
Class D/E for therapeutic administration. This terminal descriptor answers only the population, route, exposure and outcome actually observed; it neither upgrades nor cancels a different link in MOTS-c’s causal chain.
Translation rule applied
Human exogenous exposure, immunogenicity and a validated administered-peptide target-engagement signature. An exercise-associated endogenous signal does not prove that injection reproduces exercise adaptation or benefits cellular regeneration.
Falsification rule applied
The interpretation must change if any of its decisive propositions fail. For MOTS-c, the predeclared tests are: Failure of authenticated peptide to reproduce purine/AMPK signatures would weaken the core mechanism. Absence of human exposure or target engagement after administration would block therapeutic translation. Impaired repair or increased senescence markers would falsify a generic regeneration claim even if metabolic signalling occurs. These are active boundaries on the conclusion, not research questions appended after a favourable narrative.
Foundational synthesis
Molecular identity and entity resolution
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial 12S rRNA. Endogenous MOTS-c and an administered preparation are related scientific questions, not interchangeable evidence.
Foundational synthesis
Biochemical mechanism and target architecture
Experimental work connects MOTS-c with folate-cycle stress, de novo purine synthesis, AMPK activation, glucose utilisation and mitochondrial-to-nuclear signalling.
Foundational synthesis
In-vivo pharmacology and exposure
Exogenous administration improves selected metabolic and performance outcomes in animal models. Human pharmacokinetics, immunogenicity and target-engagement after administration remain insufficiently characterised.
Foundational synthesis
Integrated physiology and individual terrain
MOTS-c biology connects mitochondrial stress sensing with cytosolic purine metabolism, AMPK and nuclear adaptation. The sign of that response depends on energy state, tissue, age and proliferative demand: an energy-conservation programme may improve metabolic resilience yet constrain growth or repair in another compartment. Endogenous concentration and injected exposure are separate physiological questions.
Foundational synthesis
Terminal human stress-test
Human studies associate circulating MOTS-c with metabolic status, PCOS, insulin resistance, muscle biology and exercise. These observations illuminate endogenous physiology but do not establish therapeutic efficacy.
Foundational synthesis
Counterevidence and causal boundaries
At the evidence cutoff, no adequate randomised human efficacy trial of native exogenous MOTS-c was identified. Association and exercise response cannot substitute for administered-product exposure.
Foundational synthesis
Scientific conclusion
MOTS-c has a strong mechanistic research programme and incomplete clinical translation. A credible human programme should resolve PK, immunogenicity and target engagement before broad energy or performance outcomes.
Extended analysis
Mitochondrial coding and identity
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame within mitochondrial 12S rRNA. Its discovery expanded the mitochondrial genome from a passive template for respiratory proteins to a source of signalling peptides capable of coordinating cellular and organismal metabolism.[1]
Endogenous peptide measured in plasma or tissue and an administered synthetic preparation are not the same experiment. Correlation with disease, age or exercise can establish physiological association without establishing the pharmacokinetics or efficacy of exogenous MOTS-c.[2][3][5]
Extended analysis
Folate-cycle stress, purines and AMPK
The original mechanistic work connected MOTS-c with inhibition of the folate cycle and de novo purine synthesis, accumulation of the AICAR intermediate and activation of AMPK. In mice, treatment improved insulin sensitivity and resisted diet-induced obesity under the studied conditions.[1]
AMPK activation is a central energy-stress response, not a universal endpoint of benefit. The direction of a downstream effect depends on cell type, nutrient state, duration and competing growth or repair requirements. Target engagement must therefore be connected to function rather than treated as its substitute.[1][4][7]
Extended analysis
Mitonuclear communication
Under metabolic stress, MOTS-c translocated to the nucleus in an AMPK-dependent manner and interacted with stress-responsive transcriptional programmes including antioxidant-response-element regulation. This provides a direct molecular route through which a mitochondrial-encoded peptide can change nuclear gene expression.[4]
Nuclear translocation broadens the causal model beyond a circulating metabolic hormone. It also increases the need for context-specific analysis because a transcriptional response can support adaptation in one state while impairing proliferation or repair in another.[4][7]
Extended analysis
Exercise and muscle biology
Animal work found improved physical performance across ages and increased late-life physical capacity in mice. Human components of the same programme reported changes in endogenous muscle and circulating MOTS-c with exercise, supporting a role in exercise physiology but not therapeutic equivalence.[6]
A separate human exercise experiment found modality-dependent changes in circulating mitochondrial-derived peptides. Small sample size, assay behaviour and acute timing constrain interpretation. An exercise-responsive endogenous signal does not establish that injection reproduces training adaptation.[5]
Extended analysis
Human observations and the therapeutic gap
Human studies have measured circulating MOTS-c in PCOS, insulin-resistance and exercise contexts. Lipid infusion increased circulating values and insulin attenuated that response in a small metabolic experiment. These data illuminate regulation of the endogenous peptide.[2]
At the evidence cutoff, adequate human PK, immunogenicity, dose-exposure modelling and controlled efficacy data for native exogenous MOTS-c were not established. This is the principal translation gap and cannot be filled by animal performance or human association studies.[1][2][5][6]
Extended analysis
Mechanistic counterevidence
Recent work in human mesenchymal stromal cells reported AMPK activation alongside reduced proliferation, increased senescence-associated genes and impaired reparative function in the studied models. This is valuable counterevidence: metabolic target engagement did not guarantee cellular repair.[7]
The finding does not globally invalidate MOTS-c. It demonstrates that cell state and desired outcome matter. A programme aimed at metabolic flexibility cannot assume identical effects in tissue regeneration, cancer biology or senescent-cell systems.[7]
Evidence atlas
Every claim keeps its experimental address.
12 claim units are mapped to their evidentiary layer, experimental frame and source records. The layer describes what the evidence can answer; it is not a popularity score.
| Layer | Experimental frame | Finding and boundary | Sources |
|---|---|---|---|
| IMolecular identity | Mitochondrial coding and identity · claim 1 | MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame within mitochondrial 12S rRNA. Its discovery expanded the mitochondrial genome from a passive template for respiratory proteins to a source of signalling peptides capable of coordinating cellular and organismal metabolism. | [1] |
| IMolecular identity | Mitochondrial coding and identity · claim 2 | Endogenous peptide measured in plasma or tissue and an administered synthetic preparation are not the same experiment. Correlation with disease, age or exercise can establish physiological association without establishing the pharmacokinetics or efficacy of exogenous MOTS-c. | [2][3][5] |
| II/VMechanism and physiological translation | Folate-cycle stress, purines and AMPK · claim 1 | The original mechanistic work connected MOTS-c with inhibition of the folate cycle and de novo purine synthesis, accumulation of the AICAR intermediate and activation of AMPK. In mice, treatment improved insulin sensitivity and resisted diet-induced obesity under the studied conditions. | [1] |
| IVIntegrated in-vivo model | Folate-cycle stress, purines and AMPK · claim 2 | AMPK activation is a central energy-stress response, not a universal endpoint of benefit. The direction of a downstream effect depends on cell type, nutrient state, duration and competing growth or repair requirements. Target engagement must therefore be connected to function rather than treated as its substitute. | [1][4][7] |
| II/VMechanism and physiological translation | Mitonuclear communication · claim 1 | Under metabolic stress, MOTS-c translocated to the nucleus in an AMPK-dependent manner and interacted with stress-responsive transcriptional programmes including antioxidant-response-element regulation. This provides a direct molecular route through which a mitochondrial-encoded peptide can change nuclear gene expression. | [4] |
| IVIntegrated in-vivo model | Mitonuclear communication · claim 2 | Nuclear translocation broadens the causal model beyond a circulating metabolic hormone. It also increases the need for context-specific analysis because a transcriptional response can support adaptation in one state while impairing proliferation or repair in another. | [4][7] |
| VIHuman exposure or signal | Exercise and muscle biology · claim 1 | Animal work found improved physical performance across ages and increased late-life physical capacity in mice. Human components of the same programme reported changes in endogenous muscle and circulating MOTS-c with exercise, supporting a role in exercise physiology but not therapeutic equivalence. | [6] |
| VIHuman exposure or signal | Exercise and muscle biology · claim 2 | A separate human exercise experiment found modality-dependent changes in circulating mitochondrial-derived peptides. Small sample size, assay behaviour and acute timing constrain interpretation. An exercise-responsive endogenous signal does not establish that injection reproduces training adaptation. | [5] |
| VIHuman exposure or signal | Human observations and the therapeutic gap · claim 1 | Human studies have measured circulating MOTS-c in PCOS, insulin-resistance and exercise contexts. Lipid infusion increased circulating values and insulin attenuated that response in a small metabolic experiment. These data illuminate regulation of the endogenous peptide. | [2] |
| VIHuman exposure or signal | Human observations and the therapeutic gap · claim 2 | At the evidence cutoff, adequate human PK, immunogenicity, dose-exposure modelling and controlled efficacy data for native exogenous MOTS-c were not established. This is the principal translation gap and cannot be filled by animal performance or human association studies. | [1][2][5][6] |
| VIHuman exposure or signal | Mechanistic counterevidence · claim 1 | Recent work in human mesenchymal stromal cells reported AMPK activation alongside reduced proliferation, increased senescence-associated genes and impaired reparative function in the studied models. This is valuable counterevidence: metabolic target engagement did not guarantee cellular repair. | [7] |
| IVIntegrated in-vivo model | Mechanistic counterevidence · claim 2 | The finding does not globally invalidate MOTS-c. It demonstrates that cell state and desired outcome matter. A programme aimed at metabolic flexibility cannot assume identical effects in tissue regeneration, cancer biology or senescent-cell systems. | [7] |
Methods and coverage
A reproducible boundary, not an implied exhaustive review.
This is a curated mechanistic monograph built from primary records. It does not claim systematic-review completeness. Absence of a retrieved result is not evidence that an effect is absent.
- SEARCH SURFACE
- PubMed/MEDLINE primary records, Russian-language indexed abstracts, and reference-chaining for entity-defining, historical and translational studies. Language, geography, regulatory status and journal fashion are not evidence grades.
- QUERY FRAME
- MOTS-c · mitochondrial-derived peptide · 12S rRNA · AMPK · folate cycle · purine synthesis · mitonuclear signalling
- EVIDENCE CUTOFF
- 23 August 2026
- ENTITY EXCLUSION
- Endogenous MOTS-c concentration, genotype and synthetic exogenous administration are different scientific objects. Association studies cannot supply administered-product PK.
- TRACEABILITY
- 12 extended claim units plus 2 historical records and 3 mechanistic-calculus records; 7 cited records in the complete corpus.
- INTERPRETIVE RULE
- Identity → physical constraint → measured reaction or binding → reachable exposure → system response → outcome. Statistical significance does not manufacture mechanism; mechanistic plausibility does not manufacture a patient outcome.
Falsification map
What could make the proposition wrong?
A scientific monograph must state not only why a mechanism may hold, but what observation would weaken or overturn the inference.
- 01Failure of authenticated peptide to reproduce purine/AMPK signatures would weaken the core mechanism.
- 02Absence of human exposure or target engagement after administration would block therapeutic translation.
- 03Impaired repair or increased senescence markers would falsify a generic regeneration claim even if metabolic signalling occurs.
Research agenda
What would materially change the conclusion?
A useful research agenda resolves the weakest link in the identity-to-outcome chain. It does not merely add more observations of the same type.
- 01First-in-human exogenous PK and immunogenicity
- 02Validated assays distinguishing endogenous from administered peptide
- 03Human target-engagement biomarkers
- 04Context-specific effects on senescence and repair
- 05Controlled metabolic and functional outcomes
- 06Sequence-variant effects across mitochondrial haplogroups
Cited primary evidence corpus
7 source records used in this publication.
Reference numbers resolve directly to indexed records. This corpus documents the claims made here; it is not presented as an exhaustive systematic-review search. Index access does not upgrade the evidentiary class of a study.
- [1]Lee et al. Cell Metab. 2015;21:443–454.PMID 25738459 ↗
- [2]Ramanjaneya et al. Clin Endocrinol. 2019;91:278–287.PMID 31066084 ↗
- [3]Kumagai et al. Am J Physiol Endocrinol Metab. 2021.PMID 33554779 ↗
- [4]Kim et al. MOTS-c translocates to the nucleus to regulate nuclear gene expression under metabolic stress. Cell Metab. 2018.PMID 29983246 ↗
- [5]D'Souza et al. Acute endurance exercise stimulates circulating mitochondrial-derived peptides in humans. J Appl Physiol. 2021.PMID 34351816 ↗
- [6]Reynolds et al. MOTS-c is an exercise-induced regulator of age-dependent physical decline. Nat Commun. 2021.PMID 33473109 ↗
- [7]MOTS-c activates metabolic signalling but blunts reparative function in human mesenchymal stromal cells. Stem Cell Res Ther. 2026.PMID 42324588 ↗
Permanent citation
Cite this publication
Wibowo V. MOTS-c: Biochemical, Mechanistic and Physiological Monograph. Clinic Terrain Clinical Intelligence Unit. Version 5.0. Updated 23 August 2026.
https://www.clinicterrain.com/research/peptides/mots-cPublication and reference-verification method →Authorship and accountability
Valentine Wibowo, Clinical Researcher, Clinic Terrain Clinical Intelligence Unit, performed the conceptualisation, evidence synthesis, scientific interpretation and drafting. dr. I Wayan Cahyadi Surya Distira Putra, MPH completed medical review and approved the publication. Internal medical review is not represented as independent peer review.
No new patient data or human research were undertaken. The author and reviewer declare no personal financial competing interests. Clinic Terrain and Klinik Pratama Cepat Sehat provide clinical services; that institutional relationship is disclosed.